Clinical Trials and Lung Cancer Biomarkers
Justin F. Gainor, M.D., explains when a clinical trial might be right for patients with lung cancer mutations in this clip from our expert panel discussion on tumor testing. For more information and to see the full recorded discussion, visit Lung.org/tumor-testing-videos.
Generously supported by AstraZeneca, Bristol-Myers Squibb, Foundation Medicine, Pfizer, and Merck & Co., Inc.
When is a clinical trial right for someone that has a lung cancer mutation?
A lot of people have strong feelings when they hear clinical trial, thinking 'oh, it's just because I've exhausted other options,' and I want to emphasize that is not the case. If someone has one of these genetic changes that is actionable, where we know a lot about it, but it’s not approved yet, I would argue that for those people, depending on what the target is, sometimes a clinical trial may be the most appropriate very first therapy.
Page Last Updated: November 9, 2018
Sign up for the latest lung health news delivered right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.